Journal Guide

Nitric Oxide: Biology and Chemistry includes original research, methodology papers and reviews relating to nitric oxide and other gasotransmitters such as hydrogen sulfide and carbon monoxide. Special emphasis is placed on the biological chemistry, physiology, pharmacology, enzymology and pathological significance of these molecules in human health and disease. The journal also accepts manuscripts relating to plant and microbial studies involving these molecules.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of targeted radiotracers. The importance of the target to a key disease should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed. Supplemental information on the Aims and Scope can be found in the Jan issue of the Journal and at www.nucmedbio.com.

This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies. Peer Review Policy: All research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymous refereeing by two experts in the field. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

Oncogene covers all aspects of the structure and function of oncogenes, especially: * Cellular oncogenes and their mechanism of activation * Structure and function of their encoded proteins * Oncogenes of the DNA and RNA tumour viruses * The molecular oncology of human tumours * Tumour suppressor genes * Growth regulatory genes * Cell cycle control * Growth factors and receptors * Apoptosis * Immortalisation and cellular senescence.

Brought to you by the editorial team of Oncogene, Oncogenesis is a peer-reviewed online journal that publishes full-length papers exploring the molecular basis of cancer and related phenomena. It seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics.

The field of haemostasis and thrombosis has witnessed significant developments during the last few decades. While the upcoming of biochemistry, cell biology and later of molecular biology as new research tools has constantly been reflected in the journal, it nevertheless continues to devote many of its pages to traditional clinical pathophysiology.The journal features original contributions reporting the latest findings on the pathology, physiology and biochemistry of haemorrhagic disease and thrombosis as well as on their diagnosis and treatment. In addition to in-depth studies of such topics as blood coagulation factors, fibrinolysis, platelets and vascular biology, readers will find extensive data on clinical results with heparin, oral anticoagulants and newer anti-thrombotics.These experimental and clinical investigations are supported by occasional authoritative reviews to make the journal a full record of current research on thrombosis and haemostasis and its clinical implications.

* Biological Abstracts® (Thomson ISI) * BIOSIS Previews® (Thomson ISI) * Biotechnology & Bioengineering Abstracts (CSA/CIG) * Biowizard (Biowizard) * CAB Abstracts® (CABI) * Cambridge Scientific Abstracts (CSA/CIG) * Chemical Abstracts Service/SciFinder (ACS) * CSA Biological Sciences Database (CSA/CIG) * CSA Environmental Sciences & Pollution Management Database (CSA/CIG) * Current Awareness in Biological Sciences (Elsevier) * Current Contents®/Life Sciences (Thomson ISI) * EMBASE/Excerpta Medica (Elsevier) * Google Scholar * Index Copernicus (IC) * Index Medicus/MEDLINE/PubMed (NLM) * Journal Citation Reports/Science Edition (Thomson ISI) * PASCAL Database (INIST/CNRS) * Reference Update (Thomson ISI) * Science Citation Index Expanded® (Thomson ISI) * Science Citation Index® (Thomson ISI) * SCOPUS (Elsevier).

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Oncology Research and Treatment offers an interdisciplinary forum for cancer research and treatment. Peer-reviewed original and review articles cover a wide range of aspects in medical hematology and oncology, surgical, gynecological, pediatric, and urological oncology, dermatological oncology, diagnostics, radiation oncology, psychological care, pathology, clinical-translational oncology, and oncological rehabilitation. Oncology Research and Treatment is addressed to clinicians and practitioners working and researching in the field of hematology and oncology.
The focus of Oncology Research and Treatment is to report clinical and translational research. Basic research is not in the scope of the journal.

Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck.Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.Basic, translational, or clinical Research or Review papers of high quality and that make a contribution to new knowledge are invited on the following aspects of neoplasms arising in the head and neck (including lip, tongue, oral cavity, oropharynx, salivary glands, sinuses, nose, nasopharynx, larynx, skull base, thyroid, and craniofacial region, and the related hard and soft tissues and lymph nodes):• Etiopathogenesis: natural history of cancer and pre-cancer; basic pathology, metastatic mechanisms; genetic changes; cellular and molecular changes; microorganisms; growth factors, adhesion and other molecules• Epidemiology; risk factors; biomarkers; protective factors; geographic factors; prevention; screening and intervention• Clinical features; orofacial effects of neoplasms at both local and distant sites; tumor staging and grading• Diagnosis; detection of cancer and pre-cancer; cellular and molecular markers for diagnosis; advances in imaging and other functional diagnostic modalities for cancer and pre-cancer• Management and Prognosis; clinical, cellular and molecular markers for prognosis; treatment options including surgical, lasers, photodynamic therapy, cryosurgery, micro- vascular and other forms of surgery, medical, radiotherapy, chemotherapy, immunotherapy, biological and gene therapy advances; molecular targets and new therapeutics (new cytotonics and molecular-targeted therapies); multimodality treatment; advances in reconstruction and rehabilitation, including flaps and grafts, alloplasty, bone and connective tissue biology; multidisciplinary teamwork in cancer care and oral health care.• Quality of life issues; issues of consent; psychosocial aspects; patient and health professional information; patient involvement; psychological interventions, improving outcomes; the prevention, diagnosis and management of complications, including, pain, hemorrhage, dysfunction, deformity, osteoradionecrosis, xerostomia, and others; rehabilitation; palliative and end of life care; and support teamwork.

Genetics and genomics research has grown at a bewildering pace in the past 15 years. The techniques of these fields are being applied to a wealth of biological questions and experimental systems. PLoS Genetics reflects the full breadth and interdisciplinary nature of this research by publishing outstanding original contributions in all areas of biology.PLoS Genetics publishes human studies, as well as research on model organisms—from mice and flies, to plants and bacteria. Our emphasis is on studies of broad interest that provide significant mechanistic insight into a biological process or processes. Topics include (but are not limited to) gene discovery and function, population genetics, genome projects, comparative and functional genomics, medical genetics, disease biology, evolution, gene expression, complex traits, chromosome biology, and epigenetics.Please refer to our Author Guidelines and Frequently Asked Questions when you are preparing manuscripts for submission. If you are unsure whether your work is suitable for PLoS Genetics, you can send a Presubmission Inquiry.

Pathology & Oncology Research (POR) is an interdisciplinary journal at the interface of pathology and oncology, including the preclinical and translational research, diagnostics and therapy. Furthermore, POR offers an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments in its focused biomedical fields which span the gap between basic research and clinical medicine. A special aim of POR is to promote publishing activity in pathology and oncology of colleagues in the Central and East European region. The journal will interest pathologists, and a broad range of experimental and clinical oncologists, and related experts. Pathology & Oncology Research is supported by distinguished international advisory board and the Arányi Foundation for modern pathology.

Prostate Cancer is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies related to all aspects of prostate cancer.

Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management.Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, BPH and prostatitis.Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.The following is a non-exhaustive list of the general topics covered by Prostate Cancer and Prostatic Diseases: * Alternative therapies * Angiogenesis * Anti-sense oligonucleotides against growth factors * Brachytherapy * Conformal radiotherapy * Cryotherapy * Cyclotron fast neutron treatment * Enhancing the results of radical prostatectomy * Epidemiology of prostate cancer and prostatic diseases * Familial prostate cancer * Free to total PSA * Gene therapy for prostate cancer * Genetic basis for prostate cancer Hormone-related disease * How significant is PSA-detected disease? * Intermittent antiandrogen therapy * Mechanisms of tumour invasion in prostate cancer * Medical and surgical therapies for BPH * Medical therapy for BPH: the road ahead * Natural history of prostate cancer and prostatic diseases * Nutrition in prostate cancer and prostatic diseases * Photodynamic therapy * Prognostic markers * Prostate cancer and potency and impotence * Prostatic intra-epithelial neoplasia - an important precursor of cancer * Prostatitis: quo vadis? * Quality of life issues * Racial issues in prostate cancer * Recurrence after radical prostatectomy * Reproducibility (test-retest reliability) of investigations for prostatic diseases * Reverse transcriptase polymerase chain reaction to detect circulating mRNA for PSA * Role of differentiation therapy * Screening for prostate cancer * Staging of prostate cancer: beyond conventional imaging * The magic bullet - use of PSA promotor gene to target gene therapy * Utility of ultrasensitive PSA assays.

RSC Chemical Biology is a gold open access journal dedicated to publishing and disseminating exceptional, breakthrough research and high-quality reviews at the interface of chemistry and biology. We welcome contributions from across the breadth of the chemical biology field. This includes Sensing and Imaging, Bioorthogonal chemistry, Biosynthesis, Biomimetics and Bioengineering, Synthetic biology, Directed evolution, Drugs development and mechanism of action, Glycoscience, Natural products, Nucleic acids, Peptides, Phenotypic screening, Proteins (including protein-protein interactions, modifications, structure and function) We are particularly interested in reports on the application of chemical tools to probe, explore and visualize biological systems and processes to provide insights into molecular mechanisms in health and disease. We also encourage translational research that bridges chemistry and chemical biology to medicine.

RSC Medicinal Chemistry publishes significant research in medicinal chemistry and related drug discovery science. Research articles published in RSC Medicinal Chemistry must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field. Topics within the journal's scope include, but are not limited to: design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities; modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value; novel methodologies and technologies in the broader chemical and biological sciences; computational, machine learning and artificial intelligence (AI) studies are welcome where they significantly advance medicinal chemistry knowledge; studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics; studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence; studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors.